Impact ofKRASmutation and PTEN expression on cetuximab-treated colorectal cancer
作者： Fang-Hua Li , Lin Shen , Zhuang-Hua Li , Hui-Yan Luo , Miao-Zhen Qiu
关键词: Colorectal cancer 、 Cancer research 、 Regimen 、 Tensin 、 Gastroenterology 、 Chemotherapy 、 PTEN 、 Monoclonal 、 Cetuximab 、 Internal medicine 、 Medicine 、 Immunohistochemistry 、 General Medicine
摘要: AIM: To investigate the prognostic value of KRAS mutation, and phosphatase tensin (PTEN) expression in Chinese metastatic colorectal cancer (mCRC) patients treated with cetuximab. METHODS: Ninety mCRC cetuximab were evaluated for mutation PTEN protein by DNA sequencing codons 12 13 immunohistochemistry, respectively. We then selected 61 cetuximab, either combination chemotherapy, or alone as a second-line third-line regimen to assess whether is associated response survival time cetuximab. RESULTS: was found 30 (33.3%) tumor samples from 90 patients, positive detected 58 (64.4%) patients. Among who regimen, resistance 22 39 without rate 4.5% 46.1% respectively (P = 0.001), shorter median progression-free (PFS) 14 ± 1.3 wk 32 2.5 < overall (OS) 11 1.2 mo 19 1.8 well 24 negative 37 responsive 4.2% 48.6% respectively, PFS 17 2.0 28 1.9 0.07), OS 18 0.004). Combined analysis showed that two favorable factors longer than those one factor no 0.001). CONCLUSION: are significantly correlated cetuximab.
sci-hub.st 参考文章(23)
Sufi Mary Thomas, Jennifer Rubin Grandis, Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Reviews. ,vol. 30, pp. 255- 268 ,(2004) , 10.1016/J.CTRV.2003.10.003
Pier Paolo Pandolfi, Breast cancer--loss of PTEN predicts resistance to treatment. The New England Journal of Medicine. ,vol. 351, pp. 2337- 2338 ,(2004) , 10.1056/NEJMCIBR043143
John Marshall, Clinical implications of the mechanism of epidermal growth factor receptor inhibitors Cancer. ,vol. 107, pp. 1207- 1218 ,(2006) , 10.1002/CNCR.22133
Yuji Aoki, Shigetoshi Hosaka, Naoki Tachibana, Yasuyuki Karasawa, Shigeyuki Kawa, Kendo Kiyosawa, Reassessment of K-ras mutations at codon 12 by direct PCR and sequencing from tissue microdissection in human pancreatic adenocarcinomas. Pancreas. ,vol. 21, pp. 152- 157 ,(2000) , 10.1097/00006676-200008000-00008
J Baselga, The EGFR as a target for anticancer therapy--focus on cetuximab. European Journal of Cancer. ,vol. 37, pp. 16- 22 ,(2001) , 10.1016/S0959-8049(01)00233-7
Wu Zhang, Michael Gordon, Oliver A. Press, Katrin Rhodes, Daniel Vallböhmer, Dong Yun Yang, David Park, William Fazzone, Anne Schultheis, Andy E. Sherrod, Syma Iqbal, Susan Groshen, Heinz-Josef Lenz, Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab Pharmacogenetics and Genomics. ,vol. 16, pp. 475- 483 ,(2006) , 10.1097/01.FPC.0000220562.67595.A5
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, Rafael G. Amado, Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 25, pp. 1658- 1664 ,(2007) , 10.1200/JCO.2006.08.1620
Fotios Loupakis, Luca Pollina, Irene Stasi, Annamaria Ruzzo, Mario Scartozzi, Daniele Santini, Gianluca Masi, Francesco Graziano, Chiara Cremolini, Eliana Rulli, Emanuele Canestrari, Niccola Funel, Gaia Schiavon, Iacopo Petrini, Mauro Magnani, Giuseppe Tonini, Daniela Campani, Irene Floriani, Stefano Cascinu, Alfredo Falcone, PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 2622- 2629 ,(2009) , 10.1200/JCO.2008.20.2796
Andrea Sartore-Bianchi, Miriam Martini, Francesca Molinari, Silvio Veronese, Michele Nichelatti, Salvatore Artale, Federica Di Nicolantonio, Piercarlo Saletti, Sara De Dosso, Luca Mazzucchelli, Milo Frattini, Salvatore Siena, Alberto Bardelli, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Research. ,vol. 69, pp. 1851- 1857 ,(2009) , 10.1158/0008-5472.CAN-08-2466